Press Releases

Press Releases

Date	Title
Sep 29, 2024	Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024
Sep 26, 2024	Alnylam to Webcast TTR Investor Day
Aug 30, 2024	Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
Aug 28, 2024	Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Aug 07, 2024	Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
Aug 01, 2024	Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
Jul 18, 2024	Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
Jun 24, 2024	Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
May 07, 2024	Alnylam Issues 2023 Corporate Responsibility Report
May 02, 2024	Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity

For Media Inquiries, please contact:

Christine Lindenboom

SVP, Investor Relations & Corporate Communications media@alnylam.com 617-682-4340

For Investor Inquiries, please contact:

Josh Brodsky

VP, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276

MEDIA KIT

Essential assets and documents related to Alnylam

Looking for specific information that isn't listed above?